Jonathan Pollock

Jonathan Pollock serves as a key procurement lead within the National Institute on Drug Abuse (NIDA), supporting the agency’s mission to advance scientific research on substance use disorders through strategic acquisition of specialized scientific and clinical services. He manages a portfolio of research-supporting contracts focused on diagnostic imaging infrastructure and data-driven behavioral health studies, ensuring that funded institutions have the technical and operational resources necessary to translate laboratory findings into clinical applications. His acquisitions are primarily performance-based, emphasizing rigorous scientific deliverables, data interoperability, and compliance with NIH-wide research standards. Pollock maintains longstanding relationships with leading academic medical centers, including The McLean Hospital Corporation, the University of Maryland, Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These institutions serve as primary recipients for complex, multi-year research support contracts involving neuroimaging systems, longitudinal data collection platforms, and clinical trial infrastructure. His contracting approach emphasizes collaboration with high-capacity research entities capable of delivering large-scale, multi-site studies with stringent methodological oversight. Pollock’s procurement activity is entirely non-set-aside, with 100% of awards issued under full and open competition. This reflects NIDA’s operational emphasis on scientific merit and technical capacity over socioeconomic preferences, prioritizing the highest-quality research execution regardless of vendor size or certification status. While small business participation is not structurally mandated, contractors are evaluated on scientific rigor, institutional capacity, and past performance. His primary NAICS focus is 621512 (Diagnostic Imaging Centers), indicating a strong specialization in procuring advanced neuroimaging services, including MRI, PET, and fMRI infrastructure, as well as associated data analysis and behavioral assessment tools. He routinely acquires imaging hardware, software platforms for neuroinformatics, and integrated clinical research environments that support NIDA’s translational research agenda in addiction neuroscience.